Compare Merck & Co., Inc. (MRK) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Omnicom Group Inc. — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Omnicom Group Inc. trades at $78.55 (market cap $22.26B). The key difference: Merck & Co., Inc. is far larger — about 16.5× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (3.94%). Which is the better fit depends on your goals.
| MRK | OMC | |
|---|---|---|
Market Cap | $366.28B | $22.26B |
Sector | Health | Media |
52-Week High | $156.43 | $88.94 |
52-Week Low | $77.60 | $67.27 |
Enterprise Value | $413.04B | $30.33B |
Dividend Yield | 2.29% | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Omnicom Group (OMC) trades at $81.13, down 1.8% on the day, with a bearish technical outlook and mixed quarterly earnings performance. The company reported strong revenue growth to $17.27 billion in 2025 but posted a net loss of $54.5 million due to acquisition costs. Analyst consensus remains cautious with a 'Hold' rating despite a $96.50 price target representing 19% upside potential. Recent leadership transitions and media agency consolidation signal strategic repositioning amid challenging market conditions.
OMC presents a value opportunity with attractive valuation multiples (P/S: 0.91x, P/B: 2.3x) and a 4% dividend yield, but faces integration risks from the Interpublic acquisition and margin pressure. The stock's near-term trajectory depends on successful cost synergies and organic growth acceleration beyond current 6.1% levels. Debt levels have increased substantially post-acquisition, requiring careful monitoring of cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
